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Human bone marrow mesenchymal stromal cells express the neural ganglioside
GD2: a novel surface marker for the identification of MSCs
Caridad Martinez,1 Ted J. Hofmann,1 Roberta Marino,1,2 Massimo Dominici,3 and Edwin M. Horwitz1
1Division of Bone Marrow Transplantation, St Jude Children’s Research Hospital, Memphis, TN; 2Department of Pediatrics, Federal University of Sao Paulo,
Brazil; and 3Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
Mesenchymal stromal cells (MSCs) have
enormous potential for the regeneration
of bone, cartilage, and other tissues de-
rived from primitive mesoderm. Despite
extensive research, there is still no single
marker that reliably identifies MSCs within
the bone marrow. Using immunocyto-
chemistry and flow cytometry, we demon-
strate here that the neural ganglioside
GD2 is expressed by MSCs either newly
isolated from bone marrow or expanded
in tissue culture; this finding was supported
by reverse transcriptase–polymerase chain
reaction (RT-PCR) analysis showing ex-
pression of the mRNA for GD2 synthase,
an essential enzyme for GD2 biosynthe-
sis. GD2 was also expressed on MSCs
isolated from adipose tissue, but not on
foreskin fibroblasts. Importantly, MSCs
were the only cells within normal marrow
that expressed this marker. Thus, GD2
appears to be the first reported single
surface marker that uniquely distin-
guishes MSCs from other marrow ele-
ments. GD2 may prove valuable to study
MSC biology and for the preparation of
MSCs for clinical applications. (Blood.
2007;109:4245-4248)
© 2007 by The American Society of Hematology
Introduction
Human mesenchymal stromal cells (MSCs) are multipotent progeni-
tors that can differentiate to bone, fat, cartilage, and other
mesenchymal tissues.1,2 Termed mesenchymal stem cells by some
investigators, MSCs can be isolated from a variety of tissues, but
those from bone marrow are the most widely studied and best
characterized. Interest in MSCs for diverse applications has grown
rapidly over the last decade3-6; however, a single surface marker
that would uniquely identify this population of cells within the
bone marrow remains elusive.2
The first monoclonal antibodies used to characterize MSCs
were SH2 and SH3,7 which later were shown to recognize epitopes
on CD1058 and CD73,9 respectively. While these antigens remain
the cornerstone of human MSC identification,2 they are also
expressed on hematopoietic and endothelial cells. GD2 is a
disialoganglioside found mainly in the nervous system. Reports of
neural antigen expression on MSCs10,11 led us to consider that these
cells might express GD2, which could be a useful marker of MSCs,
as its expression should not extend to hematopoietic cells or other
normal marrow elements. Here, we demonstrate the expression of
GD2 by MSCs but not other cells within the bone marrow,
suggesting that this antigen might serve as a single definitive
marker of marrow-derived MSCs.
Materials and methods
Isolation of human MSCs
Bone marrow MSCs (from multiple donors) were isolated according to a
protocol approved by the institutional review board of St Jude Children’s
Research Hospital, Memphis, TN, as previously described.12 Adipose-
derived MSCs were obtained from tissue generously provided by Dr Jeffrey
Gimble according to a standard protocol described elsewhere.13
Immunocytochemistry
We performed immunocytochemical studies on a formalin-fixed cell
culture expanded on a sterile chamber slide, using a murine monoclonal
antibody against GD2 (clone 14.G2A; BD Biosciences, San Jose, CA).
The reaction was visualized with a biotinylated goat antimouse second-
ary antibody with ABC substrate and Nova Red as the chromogen
(Vector Labs, Burlingame, CA). All slides were lightly counterstained
with hematoxylin. Stained slides were examined on an Olympus BX41
(Olympus America, Melville, NY) with a 4/0.13 NA dry objective, and
photomicrographs were acquired using the attached SPOT RT color
camera and SPOT RT v 3.2 software (Diagnostic Instruments, Sterling
Heights, MI). Images were cropped and labeled using Photoshop 7.0 and
Illustrator 10.0 (Adobe Systems, San Jose, CA).
Reverse transcription PCR
RNA was extracted with Trizol Reagent according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). Primers for GD2 synthase were
forward 5-CCAACTCAACAGGCAACTAC-3, reverse 5-GATCATA-
ACGGAGGAAGGTC-3 (230-bp product), and forward 5-GACAAGC-
CAGAGCGCGTTA-3, reverse 5-TACTTGAGACACGGCCAGGTT-3
(99-bp product); primers for 2-microglobulin (333-bp product) were
forward 5-CTCGCGCTACTCTCTCTTTCTTGG-3, reverse 5-GCTTA-
CATGTCTCGATCCACTTAA-3. Polymerase chain reaction (PCR) con-
ditions were denaturation at 95°C for 12 minutes, then 35 cycles at 95°C
for 1 minute, 59°C for 1 minute, 72°C for 1 minute, and then 72°C for
10 minutes.
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Figure 1. GD2 expression on marrow MSCs. (Ai) Photomicrograph of undifferentiated MSCs showing the characteristic spindle shape and adherent properties of the cells.
Original magnification, 40. (ii) Flow cytometry histograms demonstrating the typical expression pattern of surface antigens (—) isotype and control (- - -), as indicated. (iii-v)
Immunocytochemical staining demonstrating the differentiation of MSCs into osteoblasts (Alizarin Red stain), adipocytes (Oil Red O stain), and chondroblasts (Alcian Blue
stain). (B) Immunocytochemical staining of culture-expanded MSCs for GD2 (i) and staining without the primary anti-GD2 antibody as a negative control (ii). (iii) Flow cytometry
histogram showing GD2 expression (bold line) by MSCs and the isotype control (thin line). (iv) Reverse-transcription PCR for GD2 synthase. Results using primers generating
a 230-bp product are shown at the top, primers generating a 99-bp product are in the middle, and 2-microglobulin as a control for the quality and quantity of RNA is at the
bottom. No RNA indicates a complete reaction omitting the RNA sample; NB, RNA from neuroblastoma cells (positive control), MSC, culture-expanded after marrow derivation;
MNCs, RNA from blood mononuclear cells (negative control); No RT, reaction with MSC RNA, but omitting reverse transcriptase. (Ci) Flow cytometry histogram of bone marrow
cells for CD45 expression. The R1 gate indicates CD45 cells. (ii) Analysis of the CD45 cells from the R1 gate for CD105 and CD73 expression. The R2 gate indicates the
double-positive cells. (iii) Analysis of the CD45CD105 CD73 cells from the R2 gate for GD2 expression. These cells, MSCs from freshly harvested bone marrow, were never
in tissue culture. (D) Flow cytometry histograms of GD2 expression on MSCs after serial passage in tissue culture. The experimental and control curves are as indicated in
panel B. (E) Immunocytochemical staining of adipose-derived MSCs (i) and a negative control (ii) in which the primary anti-GD2 antibody was omitted. The specimens were
lightly counterstained with hematoxylin. Original magnification, 4. Immunocytochemical staining of foreskin fibroblasts (iii) and a negative control (iv) as for the
adipose-derived MSCs. Original magnification,4. (Fi) Flow cytometric histograms showing the lack of GD2 expression on unfractionated bone marrow cells (upper left, BM),
and on marrow cells expressing CD45 (leukocytes), CD34 (hematopoietic progenitors), CD33 (myeloid cells), CD3 (T-lymphocytes), or CD19 (B-lymphocytes). anti-GD2
antibody (—), isotype control (- - -). (ii) Anti-GD2 immunohistochemical staining of a bone marrow biopsy specimen (left) and MSCs (right, positive control). Both specimens
were counterstained with hematoxylin.
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MSC differentiation
Culture-expanded MSCs were differentiated in vitro to osteoblasts,14
adipocytes,15 and chondroblasts,16 as described. The differentiated osteo-
blasts were stained with Alizarin Red S,17 the adipocytes with Oil Red O,18
and the chondroblasts with Alcian Blue,19 according to published protocols.
Stained differentiated cells were imaged on a Nikon Eclipse TE300 inverted
microscope (Nikon, Melville, NY) with a 40/0.6 NA objective and an
attached Nikon D70 camera (Nikon). Images were cropped and labeled
using Photoshop 7.0 and Illustrator 10.0 (Adobe Systems).
Flow cytometry
All analyses were performed on a BD LSR II flow cytometer (BD Biosciences,
San Jose, CA), with antibodies from BD Biosciences, except that the monoclonal
antibody against human fibroblasts, clone D7-FIB, was from Serotec (Raleigh,
NC). The data were analyzed with Cell Quest Pro Software Version 5.2.1 (BD
Biosciences).
Immunoselection of MSCs
GD2-expressing MSCs were isolated from freshly harvested bone
marrow mononuclear cells using our murine monoclonal antibody
against GD2 and an allophycocyanin-conjugated donkey antimouse
secondary antibody with the corresponding magnetic beads on an
AutoMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany),
according to the manufacturer’s instructions.
Results and discussion
Human MSCs isolated from bone marrow showed the characteris-
tic features of spindle shape and plastic adherence (Figure 1Ai).
Flow cytometric analysis demonstrated the expression of distin-
guishing MSC antigens (CD105, CD73, and CD90), and the
absence of hematopoietic and endothelial antigens (CD45, CD34,
CD19, CD3, CD11b, and HLA DR; Figure 1Aii). The culture-
expanded cells were capable of in vitro differentiation to osteo-
blasts as demonstrated by Alizarin Red staining; adipocytes, as
demonstrated by Oil Red O staining; and chondroblasts as demon-
strated by Alcian Blue staining (Figure 1Aiii-v). Thus, the isolated
cells met the essential criteria used to define MSCs.2
Immunocytochemical staining of the marrow-derived MSCs re-
vealed striking expression of the neural ganglioside GD2 (Figure 1Bi).
Comparable staining was found on all MSCs, indicating a pancellular
expression of GD2 among these bone marrow elements. Staining of
MSCs without the primary antibody yielded negative results, demon-
strating the lack of nonspecific staining (Figure 1Bii). To assess
GD2 expression by an alternative method, we analyzed culture-
expanded cells by flow cytometry, finding high levels of GD2
surface expression (Figure 1Biii). Reverse-transcription PCR
analysis using 2 different primer pairs, with a neuroblastoma
cell line and blood mononuclear cells serving as positive and
negative controls, respectively, showed that MSCs expressed the
mRNA for GD2 synthase (Figure 1Biv), an essential enzyme for
GD2 biosynthesis. These results provide crucial supportive
evidence of genuine ganglioside expression on MSCs.
All cells analyzed in the preceding experiments had been
expanded for 2 passages in culture. Since GD2 can play a role in
cellular adhesion20 we considered that plastic adherence of MSCs
in vitro might induce or alter the expression of GD2 in a manner
different from the normal regulation of the ganglioside. To address
this possibility, we analyzed newly harvested bone marrow mono-
nuclear cells (MNCs) by 4-color flow cytometry, gating first on
marrow MNCs that lacked CD45 expression (Figure 1Ci, gate R1).
These cells (R1) were then analyzed for CD105 and CD73
expression (Figure 1Cii). About 95% of the CD45CD105
CD73 cells (gate R2) expressed GD2 (Figure 1Ciii). Further,
newly harvested marrow MNCs that expressed either CD271 or
D7Fib, both of which have been suggested to represent MSCs,21,22
were found to coexpress GD2 (data not shown). The intensity of
GD2 expression exceeded that of either CD271, which is lost
during culture, or D7Fib, which is also expressed on skin fibro-
blasts. Notably, the entire population of expanded MSCs continued
to express GD2 at similar levels through 8 culture passages (Figure 1D).
To determine if GD2 expression is unique to marrow-derived
MSCs, we analyzed such cells from adipose tissue. As shown in
Figure 1E, the adipose-derived cells also expressed GD2 at
approximately the same level as marrow-derived MSCs. Foreskin
fibroblasts, by contrast, lacked GD2 expression (Figure 1E).
Finally, flow cytometric analysis of unfractionated marrow
cells, leukocytes (CD45), hematopoietic progenitors (CD34), my-
eloid cells (CD33), T-lymphocytes (CD3), and B-lymphocytes
(CD19) demonstrated the absence of GD2 expression (Figure 1F).
Our RNA analysis revealed the lack of GD2 synthase expression in
circulating blood cells (Figure 1B). Most importantly, immunohis-
tochemical staining of normal bone marrow biopsy specimens
(Figure 1F) did not detect other GD2-expressing cells. Collectively,
these data indicate the lack of hematopoietic GD2 expression,
consistent with prior reports.23,24
Cells isolated from freshly harvested bone marrow by selection
for GD2 expression using immunomagnetic beads demonstrated
typical MSC morphology and plastic adherence (Figure 2). The
culture-expanded cells differentiated to osteoblasts, adipocytes,
and chondroblasts (Figure 2), as expected for MSCs.
GD2 is the first candidate marker of MSCs to be consistently
expressed at a high level on all cells of this population, whether
freshly isolated or ex vivo expanded; hence, GD2 selection may
offer an improved approach for MSC identification and isolation.
Immune recognition of the GD2-expressing MSCs in the
marrow microenvironment may underlie the hematopoietic
suppression observed when anti-GD2 antibodies are used as
immunotherapy for neuroblastoma.
A critical question in MSC biology is whether this cell
population possesses a relatively uniform differentiation capability,
and responds to specific signals to generate diverse mesenchymal
lineages, or is comprised of biologically distinct subsets of
Figure 2. Ex vivo expansion and trilineage differentiation of GD2-selected
MSCs. Photomicrograph of undifferentiated, ex vivo–expanded cells (upper panel)
after isolation by GD2 selection. The characteristic spindle shape morphology and
plastic adherence of MSCs is shown. Immunocytochemical staining (lower panels)
demonstrates the differentiation of the GD2-selected MSCs into osteoblasts (Alizarin
Red stain), adipocytes (Oil Red O stain), and chondroblasts (Alcian Blue stain).
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progenitors committed to differentiate in particular pathways. The
availability of a marker antigen such as GD2 would be useful in
resolving this issue, much in the way that CD34 has helped to
discriminate among subsets of hematopoietic progenitors.
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